1-4 of 4
Ben Tran
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer

Tanya Dorff, Lisa G. Horvath, Karen Autio, Alice Bernard-Tessier, Matthew B. Rettig, Jean-Pascal Machiels, Mehmet A. Bilen, Martijn P. Lolkema, Nabil Adra, Sylvie Rottey, Richard Greil, Nobuaki Matsubara, Daniel S.W. Tan, Alvin Wong, Hiroji Uemura, Charlotte Lemech, Johannes Meran, Youfei Yu, Mukul Minocha, Mason McComb, Hweixian Leong Penny, Vinita Gupta, Xuguang Hu, Gabor Jurida, Hosein Kouros-Mehr, Margit M. Janát-Amsbury, Tobias Eggert, Ben Tran
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (8): 1488–1500.
https://doi.org/10.1158/1078-0432.CCR-23-2978
Published: 15 April 2024
View article titled, A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer
Open the PDF for A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study

Lavinia Tan, Ben Tran, Jeanne Tie, Ben Markman, Sumi Ananda, Niall C. Tebbutt, Michael Michael, Emma Link, Stephen Q. Wong, Sushma Chandrashekar, Jerick Guinto, David Ritchie, Rachel Koldej, Benjamin J. Solomon, Grant A. McArthur, Rodney J. Hicks, Peter Gibbs, Sarah-Jane Dawson, Jayesh Desai
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (6): 1017–1030.
https://doi.org/10.1158/1078-0432.CCR-22-3094
Published: 14 March 2023
View article titled, A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in <em>BRAF</em> V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study
Open the PDF for A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in <em>BRAF</em> V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study in another window
Includes: Supplementary data
Journal Articles

Abstract A24: Identifying the genomic and clinical features of AKT1/PIK3CA mutant metastatic prostate cancer using circulating tumor DNA

Cameron M. Herberts, Andrew J. Murtha, Simon Fu, Gang Wang, Elena Schönlau, Anna Gleave, Steven Yip, Arkhjamil Angeles, Sebastien Hotte, Abdulraheem Alshangiti, Ben Tran, Scott North, Sinja Taavitsainen, Kevin Beja, Gillian Vandekerkhove, Elie Ritch, Fred Saad, Nayyer Iqbal, Martin E. Gleave, Matti Annala, Kim N. Chi, Alexander W. Wyatt
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (11_Supplement): A24.
https://doi.org/10.1158/1557-3265.LiqBiop20-A24
Published: 01 June 2020
View article titled, Abstract A24: Identifying the genomic and clinical features of AKT1/PIK3CA mutant metastatic prostate cancer using circulating tumor DNA
Journal Articles

Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repair–Proficient Stage II Colon Cancer

Pradipta Ghosh, Jeanne Tie, Andrea Muranyi, Shalini Singh, Patrick Brunhoeber, Katherine Leith, Rebecca Bowermaster, Zhiming Liao, Yifei Zhu, Bonnie LaFleur, Ben Tran, Jayesh Desai, Ian Jones, Matthew Croxford, Rodrigo Jover, Ajay Goel, Paul Waring, Song Hu, Volker Teichgraber, Ulrich-Peter Rohr, Ruediger Ridder, Kandavel Shanmugam, Peter Gibbs
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (14): 3488–3498.
https://doi.org/10.1158/1078-0432.CCR-15-2290
Published: 14 July 2016
View article titled, Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repair–Proficient Stage II Colon Cancer
Open the PDF for Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repair–Proficient Stage II Colon Cancer in another window